BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:T-cell leukemia: from basic understanding towards targeted therape
 utics
DTSTART:20210910T121500
DTEND:20210910T131500
DTSTAMP:20260507T165630Z
UID:325763b65f4a8c43f6cef2cbf76ab8a6e051f1026d2b9638f1416d06
CATEGORIES:Conferences - Seminars
DESCRIPTION:Jules Meijerink Princess Máxima Center for Pediatric Oncology
 \, Utrecht\, The Netherlands\nT-cell acute lymphoblastic leukemia originat
 e from early developing T-cells in the thymus. Here\, first driving oncoge
 nic rearrangements provide a pathogenic state that freeze cells at specifi
 c stages of thymocyte development. Further acquisition of mutations involv
 ing various cellular processes and important signaling pathways give rise 
 to a fulminant leukemia. Current treatment consist of high intensity combi
 nation chemotherapy that leads to cure in approximately 70 to 80 percent o
 f the patients\, while patients who relapse have a very poor outcome despi
 te bone marrow transplantation. Research in my research group is focused o
 n the improved understanding of pathogenic mechanisms in T-ALL of which so
 me result in acquired resistance towards treatment. Improved understanding
  has led to the identification of various molecular targets for therapeuti
 c intervention\, and especially those targets that make leukemia cells res
 istant to steroid treatment\, a cornerstone drug in the treatment of ALL.
LOCATION:SV 1717 https://plan.epfl.ch/?room==SV%201717 https://epfl.zoom.u
 s/j/65608947786
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR